文献速递肾癌与肾肿瘤

乳头状肾细胞癌再探讨:世界卫生组织2022分类对预后评估的影响

Papillary renal cell carcinoma revisited: impact of the World Health Organization 2022 classification on prognostication.
PubMed 文献 · BJU Int · 2024-11-25

研究纳入1995至2022年接受手术切除的527例乳头状肾细胞癌患者,按WHO 2022标准重新分类并分析预后。29.9%的1型与57.7%的2型病例被重新分类;修订标准尤其对≤4 cm肿瘤改善了预后分层准确性。中位随访79个月,1型5年无进展生存率97%,2型80%,TFE3重排75%,FH缺陷型43.5%。

要点

  • 按WHO 2022标准,29.9%的1型与57.7%的2型乳头状肾细胞癌被重新分类。
  • 重新分类后,修订标准尤其对≤4 cm肿瘤显示出生存分层的显著差异。
  • 5年无进展生存率:1型97%、2型80%、TFE3重排75%、FH缺陷型43.5%。

核心结论

  • 修订的WHO 2022分类提高了乳头状肾细胞癌的预后准确性,尤其对小肿瘤;保留既往亚型可能具有进一步的临床与预后价值。

研究设计与样本

  • 纳入1995至2022年接受手术切除的527例乳头状肾细胞癌患者,构建组织微阵列进行免疫组化与分子表征。

主要发现

  • 初始分类:1型247例(46.9%)、2型234例(44.4%)、乳头状未特指46例(8.7%)。
  • 按修订标准,29.9%的1型与57.7%的2型病例被重新分类;重新分类后仍有373例肿瘤保留1型(254例,70%)与2型(119例,42.2%)的 distinct 组织形态学特征。
  • 中位(四分位距)随访79(38.2-132.8)个月,5年无进展生存率:1型97%、2型80%、TFE3重排75%、FH缺陷型43.5%。
  • 反向极性乳头状肾肿瘤患者未观察到疾病进展。

关键数值与推荐

  • 按WHO 2022标准重新分类,并按WHO/国际泌尿病理学会标准进行核分级。
  • 修订标准尤其对≤4 cm肿瘤在生存结局上显示出显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the impact of the revised papillary renal cell carcinoma (PRCC) classification and evaluate its validity with regard to oncological outcome stratification. PATIENTS AND METHODS: Identifying 527 patients with PRCC who underwent surgical resection from 1995 to 2022, a tissue microarray was constructed for immunohistochemical and molecular characterisation. Re-classification according to the World Health Organization (WHO) 2022 criteria and nuclear grading according to the WHO/International Society of Urological Pathologists criteria were done. In addition to the revised subtype, alleged clinicopathological prognosticators were analysed with respect to progression-free (PFS) and cancer-specific survival (CSS). RESULTS: Initially, 247 (46.9%) cases were Type 1, 234 (44.4%) were Type 2, and 46 (8.7%) were papillary not-otherwise-specified. According to the revised criteria, 29.9% of Type 1 and 57.7% of Type 2 PRCC cases were re-classified. Re-classified from Type 1 included more indolent tumours while from Type 2 PRCC many molecularly defined tumours were newly identified. After re-classification, still 373 tumours remained with distinct histomorphological features of Type 1 (254 [70%]) and Type 2 (119 [42.2%]) PRCC. Furthermore, significant differences in survival outcomes were obtained when the revised criteria was used particularly for tumours of ≤4 cm. For a median (interquartile range) follow-up of 79 (38.2-132.8) months, the 5-year PFS was 97% for Type 1, 80% for Type 2, 75% for transcription factor for immunoglobulin heavy-chain enhancer 3 (TFE3)-rearranged, and 43.5% for fumarate hydratase-deficient RCC. No disease progression was observed in patients with papillary renal neoplasm with reverse polarity. CONCLUSION: The revised WHO 2022 classification enhanced prognostic accuracy for PRCC particularly for small tumours. Retaining previous subtypes may confer further clinical as well as prognostic value.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Sung JW, Lee YI, Kim Y, et al. Papillary renal cell carcinoma revisited: impact of the World Health Organization 2022 classification on prognostication. BJU Int. 2024. PMID: 39587415. doi:10.1111/bju.16590

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。